telatinib mesylate
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2017 (NCT03175497)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
PDGFRB inhibitor
FLT4 inhibitor
- Stem cell growth factor receptorINHIBITOR
KIT inhibitor
KDR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- telatinib mesylate
- telatinib mesylate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03175497 | Phase 1 | Jun 1, 2017 | EddingPharm Oncology Co., LTD., Fountain Medical Development Co., Ltd., Fudan University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| EddingPharm Oncology Co., LTD. | For profit | 1 | 1 | 1 | 2017 |
| Fountain Medical Development Co., Ltd. | For profit | 1 | 0 | 1 | 2017 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1